Overview

Flucloxacillin as an Inducer of CYP-enzymes

Status:
Recruiting
Trial end date:
2022-01-14
Target enrollment:
Participant gender:
Summary
Worldwide there is an increase in antibiotic resistance which may have potential fatal long-term consequences. This is due to extensive use and sometimes misuse of antibiotics in the treatment of harmless infections. The aim of this study is to investigate if treatment with flucloxacillin increases drug metabolism in healthy volunteers through induction of cytochrome P450 (CYP) enzymes, CYP1A4, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The hypothesis is based on an in vitro study showing that flucloxacillin activates a receptor (PXR) responsible for transcription of CYP enzymes. Trial subjects will ingest flucloxacillin for 31 days and at day 10 and 28 ingest a cocktail of 6 drugs to determine if the CYP enzymes have been induced. Plasma and urine will be drawn over 72 hours to determine the concentration of the 6 drugs and their metabolites. Change in flucloxacillin concentration will also be measured at day 9 and 27 to establish if flucloxacillin induces its own metabolism.
Phase:
Phase 1
Details
Lead Sponsor:
University of Southern Denmark
Collaborator:
SignaTope GmbH, Germany
Treatments:
Caffeine
Efavirenz
Floxacillin
Losartan
Metoprolol
Midazolam
Omeprazole